Cell therapy company Bone Therapeutics (Euronext Brussels:BOTHE) (Euronext Paris:BOTHE) announced on Tuesday that it has completed its acquisition of a majority shareholding in Medsenic, a privately held, clinical stage biotech company.
Incorporated in France, Medsenic specialises in the development of optimised formulations of arsenic Trioxide (ATO) and their applications in serious inflammatory/autoimmune conditions and other potential new indications in related fields.
Medsenic's shareholders have contributed 51% of the total outstanding share capital of Medsenic, valued at EUR40.8m, at a subscription price per share of EUR0.45, which values Bone Therapeutics at EUR10m. In exchange for the in-kind contribution of 51% of Medsenic's shares, 90,668,594 shares were issued by Bone Therapeutics to Medsenic shareholders.
The transaction was approved during an extraordinary meeting of Bone Therapeutics' shareholders held on Monday.
Shareholders also approved Bone Therapeutics' name change to BioSenic. This will be implemented in the next few days and the company's ticker symbol on Euronext will change from 'BOTHE' to 'BIOS'. Its new corporate website will be www.biosenic.com.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP